Zydus Lifesciences is currently trading at Rs. 361.30, up by 4.10 points or 1.15% from its previous closing of Rs. 357.20 on the BSE.
The scrip opened at Rs. 357.50 and has touched a high and low of Rs. 364.20 and Rs. 357.50 respectively. So far 15513 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 592.00 on 06-Aug-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 366.00 and Rs. 342.80 respectively. The current market cap of the company is Rs. 36570.94 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 14.88% and 10.24% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin Tablets USP 10 mg and 25 mg. USRLD: Jardiance.
Empagliflozin is used to lower blood sugar levels in people with type 2 diabetes. It is also used to reduce the risk of stroke, heart attack, or death in people with type 2 diabetes along with heart and blood vessel disease. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Empagliflozin Tablets had annual sales of $9,810 million in the United States according to IQVIA data (IQVIA MAT June 2022). The group now has 319 approvals and has so far filed over 420 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.